PTK2 and familial pancreatic carcinoma: The work reported by Jiang and colleagues has seen rapid clinical translation, and has resulted in a clinical trial to test the safety, tolerability, and anti-tumour efficacy of the FAK inhibitor defactinib in combination with pembrolizumab (anti-PD-1) and gemcitabine in advanced pancreatic cancer (clinicalTrials.gov NCT02546531).